• Acceleron’s ACE-083 Earns Orphan Drug Status for Facioscapulohumeral MD
  • #PPMD2018 – Mexico Lags in Degree and Quality of Duchenne Care, Advocacy Groups Say
  • Treat Your Mental Health Before It Becomes Too Much to Bear
  • #PPMD2018 — ‘Mitchell’s Journey’ Supports Duchenne Research, Helps Families Cope with Loss
  • Phase 3 Trial of Oral Edasalonexent as Potential DMD Treatment to Open Soon, Catabasis Announces
  • #PPMD2018 – Nebraska Mother of 3 Duchenne Boys: ‘We’ve Made a Choice to Be Positive’
  • #PPMD2018 – Don’t Overlook Dental and Digestive Issues, Duchenne Experts Advise
  • Potential DMD Therapy Now in Phase 1 Trial, WVE-210201, Likely To Be Named Orphan Drug in EU
  • #PPMD2018 – Duchenne Research ‘Has Come a Long Way,’ PPMD Says at Meeting
  • 4 Approaches to Treating Duchenne Muscular Dystrophy Highlighted at PPMD Conference
  • Managing Body Temperature with Heat Intolerance
  • Cognitive Behavioral Therapy May Help Patients with Myotonic Dystrophy Type 1, Trial Shows